- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07581457
Tranexamic Acid in Pediatric Idiopathic Scoliosis Surgery
Efficacy and Safety of Two Intravenous Tranexamic Acid Regimens Versus Placebo in Pediatric Idiopathic Scoliosis Surgery: A Randomized Double-Blind Trial
This study will evaluate whether tranexamic acid (TXA), a medication used to reduce bleeding, is effective and safe in children undergoing surgery for idiopathic scoliosis. Significant blood loss is common during this type of surgery and often requires blood transfusions.
Participants will be randomly assigned to one of three groups: (1) TXA given as an intravenous bolus followed by continuous infusion, (2) TXA given as two intravenous bolus doses, or (3) placebo (saline). Neither the patients nor the medical team will know which treatment is given.
The main goal is to compare how much blood is lost during and after surgery and whether TXA reduces the need for blood transfusions. The study will also assess safety, including the risk of side effects such as seizures or blood clots.
Patients will be followed for up to 30 days after surgery.
Studie Overzicht
Toestand
Gedetailleerde beschrijving
Posterior spinal fusion for adolescent idiopathic scoliosis is associated with significant intraoperative blood loss and frequent need for blood transfusion. Tranexamic acid (TXA) is an antifibrinolytic agent that reduces bleeding, but optimal dosing strategies in pediatric scoliosis surgery remain unclear.
This study is a prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of two intravenous TXA regimens compared with placebo in children undergoing surgical correction of idiopathic scoliosis.
Participants aged 10-18 years will be randomly assigned to receive either TXA or placebo during surgery. All patients will undergo standardized anesthesia, regional analgesia, and intraoperative neuromonitoring according to institutional protocols.
The primary objective is to assess the effect of TXA on perioperative blood loss. Secondary objectives include evaluation of transfusion requirements, laboratory parameters, and safety outcomes.
Patients will be followed for 30 days after surgery to assess postoperative outcomes and adverse events.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Malgorzata Reysner, MD PhD
- Telefoonnummer: +48 61 831-01-22
- E-mail: mreysner@ump.edu.pl
Studie Contact Back-up
- Naam: Piotr Janusz, MD PhD
- E-mail: pjanusz@um.edu.pl
Studie Locaties
-
-
-
Poznan, Polen, 62-701
- Werving
- Poznan University of Medical Sciences
-
Contact:
- Malgorzata Reysner, M.D. Ph.D.
- Telefoonnummer: +48 61 873 83 03
- E-mail: mreysner@ump.edu.pl
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 10 to 18 years
- Diagnosis of idiopathic scoliosis requiring surgical correction (posterior spinal fusion)
- American Society of Anesthesiologists (ASA) physical status I-II
- Written informed consent from parents or legal guardians and assent from the child
Exclusion Criteria:
- Congenital or acquired coagulopathy
- History of thromboembolic disease
- History of seizures or epilepsy
- Known hypersensitivity to tranexamic acid
- Renal insufficiency (estimated glomerular filtration rate < 60 mL/min/1.73 m²)
- Cardiac arrhythmias or cardiovascular disease requiring antiplatelet or anticoagulant therapy
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: TXA Bolus + Infusion
Tranexamic acid administered intravenously as a 15 mg/kg bolus after induction of anesthesia, followed by continuous infusion at 1 mg/kg/h until the end of surgery. Maximum total dose not exceeding 2 g. All patients receive standardized anesthesia (TIVA with propofol and remifentanil), erector spinae plane block, and intraoperative neuromonitoring. |
Tranexamic acid administered intravenously as a 15 mg/kg bolus after induction of anesthesia, followed by continuous infusion at 1 mg/kg/h until the end of surgery.
Andere namen:
|
|
Placebo-vergelijker: Placebo
0.9% sodium chloride (saline) administered intravenously in the same volumes and timing as the active comparator groups (bolus and infusion). All patients receive standardized anesthesia (TIVA with propofol and remifentanil), erector spinae plane block, and intraoperative neuromonitoring. |
Intravenous administration of 0.9% sodium chloride solution used as placebo, matched in volume and timing to the active comparator groups.
Andere namen:
|
|
Experimenteel: TXA Bolus Only
Tranexamic acid administered intravenously as two bolus doses: 10 mg/kg after induction of anesthesia and 10 mg/kg 120 minutes after surgical incision or at the beginning of rod placement (whichever occurs first). Maximum total dose not exceeding 2 g. All patients receive standardized anesthesia (TIVA with propofol and remifentanil), erector spinae plane block, and intraoperative neuromonitoring. |
Tranexamic acid administered intravenously as two bolus doses: 10 mg/kg after induction of anesthesia and 10 mg/kg 120 minutes after surgical incision or at the beginning of rod placement, whichever occurs first.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Total Blood Loss
Tijdsspanne: 24 hours postoperatively
|
Total blood loss expressed in ml/kg |
24 hours postoperatively
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Total Volume of Blood Transfusion
Tijdsspanne: 24 hours postoperatively
|
Total volume of transfused blood products (ml/kg) administered intraoperatively and within the first 24 hours postoperatively. |
24 hours postoperatively
|
|
Hemoglobin Level
Tijdsspanne: immediately after surgery (0 hours)
|
Hemoglobin concentration measured in g/dL |
immediately after surgery (0 hours)
|
|
Hemoglobin Level
Tijdsspanne: 24 hours postoperatively
|
Hemoglobin concentration measured in g/dL |
24 hours postoperatively
|
|
Hematocrit Level
Tijdsspanne: immediately after surgery (0 hours)
|
Hematocrit value (%) |
immediately after surgery (0 hours)
|
|
Hematocrit Level
Tijdsspanne: 24 hours postoperatively
|
Hematocrit value (%) |
24 hours postoperatively
|
|
D-dimer Level
Tijdsspanne: 24 hours postoperatively
|
Plasma D-dimer concentration measured in mg/L |
24 hours postoperatively
|
|
Fibrinogen Level
Tijdsspanne: 24 hours postoperatively
|
Plasma fibrinogen concentration measured in g/L |
24 hours postoperatively
|
|
Prothrombin Time
Tijdsspanne: 24 hours postoperatively
|
Prothrombin time measured in seconds |
24 hours postoperatively
|
|
Activated Partial Thromboplastin Time
Tijdsspanne: 24 hours postoperatively
|
Activated partial thromboplastin time measured in seconds |
24 hours postoperatively
|
Medewerkers en onderzoekers
Onderzoekers
- Studie stoel: Małgorzata Reysner, MD PhD, Poznan University of Medical Sciences
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Botziekten
- Musculoskeletale aandoeningen
- Spinale ziekten
- Spinale krommingen
- Scoliose
- Organische chemicaliën
- Farmaceutische voorbereidingen
- Carbonzuren
- Anorganische chemicaliën
- Chloorverbindingen
- Crystalloid -oplossingen
- Isotone oplossingen
- Oplossingen
- Zuren, carbocyclisch
- Cyclohexanecarbonzuren
- Natriumverbindingen
- Chloriden
- Zoutzuur
- Tranexaminezuur
- Zoutoplossing
- Natriumchloride
Andere studie-ID-nummers
- 2/2026
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Individual participant data (IPD) underlying the results reported in this study, after de-identification, will be shared. This includes demographic data, perioperative variables, laboratory results, and outcome measures. Supporting documents such as the study protocol and statistical analysis plan will also be available.
IPD-tijdsbestek voor delen
Data will be available beginning 6 months after publication of the primary results and ending 5 years after publication.
IPD-toegangscriteria voor delen
Data will be shared with researchers who provide a methodologically sound proposal. Proposals should be directed to the principal investigator. Data access will be granted following approval by the study investigators and after signing a data access agreement.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .